TOKYO--(BUSINESS WIRE)--The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that Cell Therapy for Chronic Stroke, a research paper co-authored by the group’s Chief Medical Officer and Head of Medical Research, Dr. Damien Bates, and other researchers, was published in Stroke, a professional journal issued by American Heart Association. The research paper gives an overview of recent advances in R&D of therapeutic agents targeting chronic motor deficits and also reports on development progress and potential of a regenerative medicine product SB623 being developed by SanBio. The R&D covers therapy and therapeutic agents in regards to chronic motor deficit from ischemic stroke in particular, the paper summarizes characteristics, advantages, and proven efficacy of cell medicines that vary depending on origin of the cell and route of administration. Further, it reviews progress of clinical trials for the treatment of chronic motor deficit from ischemic stroke being conducted around the world.
Upon publishing the paper, Dr. Damien Bates said, “I hope this research will draw attention to regenerative medicine research for the treatment of chronic motor deficit from ischemic stroke and significantly progress establishment of effective therapeutic agents targeting patients with chronic motor deficit from ischemic stroke in the US and around the world.” Regarding SB623 being developed by SanBio, he further added, “While clinical trials of SB623 are progressing smoothly, we wish to further prepare for delivering the medicine product to the market and respond to the growing unmet medical needs in the US and around the world.”
In the SB623 development program targeting chronic motor deficit from ischemic stroke, SanBio is conducting a phase 2b clinical trial based on the results of the phase 1/2a clinical trial. Enrollment of 163 patients has already been completed, and results of the trial are scheduled to be released in the first half of the fiscal year ending January 2020 (February 2019 to July 2019) following a 12-month follow-up period. Further, SanBio has completed enrollment of 61 patients for a phase 2 clinical trial in the SB623 development program targeting chronic motor deficit from traumatic brain injury (TBI). The results of the trial are scheduled to be released in the fiscal year ending January 2019 (February 2018 to January 2019).
References:
“Update on Development Progress of Regenerative Cell
Medicine SB623,” released on April 2, 2018
SanBio, Inc. and SanBio Co., Ltd.
SanBio group is engaged in
the regenerative medicine business spanning research, development,
manufacture, and sales of regenerative medicines. In regards to its
propriety regenerative medicine product SB623, SanBio is conducting a
phase 2b clinical trial for the treatment of chronic motor deficit from
ischemic stroke in the US together with its development partner in the
US and Canada, Sumitomo Dainippon Pharma Co., Ltd. On its own, SanBio is
conducting a global phase 2 clinical trial of SB623 targeting chronic
motor deficit from TBI in Japan and the US. Headquartered in Tokyo,
SanBio has its main R&D base in Mountain View, California in the US.
